Dulaglutide

證據等級: L5

預測適應症: 10 個

Dulaglutide: From Type 2 Diabetes to Opsismodysplasia

One-Sentence Summary

Dulaglutide is a long-acting GLP-1 receptor agonist established globally for the management of Type 2 Diabetes Mellitus and cardiovascular risk reduction. The TxGNN model predicts it may be effective for Opsismodysplasia, an ultra-rare skeletal dysplasia caused by INPPL1 (SHIP2) gene mutations. Currently, no clinical trials and no published literature support this predicted direction, placing the evidence at Level 5 — model prediction only.

Quick Overview

Item	Content
Original Indication	Type 2 Diabetes Mellitus (globally established; no ARTG record retrieved in this data pull)
Predicted New Indication	Opsismodysplasia
TxGNN Prediction Score	97.05%
Evidence Level	L5
Australia Market Status	No records retrieved — ARTG verification required
Number of ARTG Entries	0
Recommended Decision	Hold

Why Is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on established pharmacology, Dulaglutide is a GLP-1 receptor agonist (GLP-1RA) that works by stimulating glucose-dependent insulin secretion, suppressing glucagon release, slowing gastric emptying, and reducing appetite via central GLP-1 receptor activation. Its proven role in Type 2 Diabetes and cardiovascular risk reduction (REWIND trial) is well-recognised internationally, though no approved indication record was retrieved in this data pull.

Opsismodysplasia is an ultra-rare autosomal recessive skeletal dysplasia caused by loss-of-function mutations in INPPL1 (SHIP2), a phosphatase that regulates the phosphoinositide signalling cascade. This disruption impairs chondrocyte differentiation and delays ossification, resulting in severe short-limb dwarfism, hypomineralisation, and frequently fatal respiratory compromise in infancy. The speculative mechanistic bridge to Dulaglutide lies in the fact that GLP-1RA signalling can modestly activate PI3K/Akt pathways downstream — pathways that partially overlap with the SHIP2-regulated phosphoinositide network.

This link is, however, mechanistically tenuous. The repurposing rationale embedded in this Evidence Pack explicitly flags that no clinical or preclinical data supports GLP-1RA use in skeletal developmental disorders. The high TxGNN score (97.05%) most likely reflects a structural artefact of the knowledge graph, where rare disease nodes with few connections can yield inflated prediction scores. This prediction should not be interpreted as a genuine therapeutic signal without further mechanistic validation.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Australia Market Information

No ARTG entries for Dulaglutide were retrieved in this data pull. Clinicians should note that Dulaglutide (Trulicity®) has TGA registration status in other data sources; the absence of records here reflects a data gap rather than confirmed non-availability. Please verify current listing directly via the TGA ARTG Public Summary.

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: All 10 TxGNN-predicted indications for Dulaglutide in this report are rated L5, supported by zero clinical trials and zero published literature. The top-ranked prediction — Opsismodysplasia — is a structurally rare disease node in the knowledge graph with no biologically plausible or empirically tested connection to GLP-1RA pharmacology; the high prediction score is almost certainly a graph topology artefact rather than a genuine therapeutic opportunity.

To proceed, the following is needed:

Confirm ARTG status: Retrieve and verify Dulaglutide’s current TGA registration and approved Australian indications directly from the ARTG database
Obtain MOA data: Query DrugBank (DB09045) to populate the missing mechanism of action — required before any mechanistic plausibility analysis can proceed
Retrieve TGA Product Information (PI): Download and parse the PI to populate key warnings and contraindications (currently blocking safety pre-screening)
Preclinical literature scoping: Commission a targeted search on GLP-1RA effects in phosphoinositide signalling disorders and skeletal dysplasia animal models before progressing this hypothesis
Rare disease specialist review: Any further investigation of Opsismodysplasia as a target indication requires input from a clinical geneticist or paediatric metabolic bone disease specialist
Reassess all 10 candidates: Three candidates in the lipodystrophy cluster (drug-induced, centrifugal, idiopathic — Ranks 5, 7, 9) carry a “Research Question” recommendation rather than “Hold” and may represent a more scientifically tractable cluster for further exploration, given GLP-1RA’s known effects on adipose tissue metabolism
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.